ClinicalTrials.gg
Status unknownNCT06017375Updated Aug 30, 2023

Patient Knowledge, Beliefs and Barriers to Hepatitis D Care

An observational study in Hepatitis, Delta, sponsored by King's College Hospital NHS Trust. Status unknown. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-30.

Sponsored by King's College Hospital NHS Trust · Observational

The sponsor has not verified this record recently (last verified Aug 2023), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
113
Ages
18 Years and older
Sex
All
01

Study summary

A project to understand the determinants of health behaviour among those with chronic hepatitis D virus (HDV) infection, under the care of the viral hepatitis service at Kings College Hospital (KCH). This is to improve and implement pathways and patient information distribution to improve access to care in an ethnically diverse population living with HDV in the UK.

Kings college hospital NHS Foundation Trust is uniquely placed and serves a large diverse population from areas such as pan pacific Asia, Eastern Europe and regions in Africa, where English is not their first language. This diversity is also seen in other London Hospitals but less so in other parts of the UK.

Read the detailed description

To understand the knowledge patients have around their diagnosis of hepatitis D which is considered a rare disease but the most aggressive form of viral hepatitis. In order to improve the management of hepatitis D, this research aims to identify the current knowledge patients have about their diagnosis, the information provided to them in their preferred language, how they feel about their diagnosis and the stigma attached. This research has been conducted in patients with other forms of viral hepatitis but not in patients living with hepatitis D. There is a lack of research in this area. With this research we aim to improve treatment pathways, access to care and to information.

02

Conditions studied

  • Hepatitis, Delta

Browse trials for

03

In context

Hepatitis D

82 studies on the registry are indexed under Hepatitis D; 24 are open to participants now.

This study's planned enrollment of 113 is below the median of 313 across 40 observational studies indexed under Hepatitis D.

Browse Hepatitis D studies →

Lead sponsor

King's College Hospital NHS Trust is the lead sponsor of 171 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Patients with past or current hepatitis D virus infection

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants 18 years or older.
  • HDV infection as diagnosed by high levels of anti-HDV immunoglobulin G (IgG) and immunoglobulin M (IgM), and confirmed by detection of HDV RNA in serum.
  • Treated HDV infection
  • Willing and able to provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Clinically significant medical or psychiatric illness in the past, present, or being evaluated, that may interfere with participant treatment, safety and assessment.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
113 participants (estimated)
Patient registry
No

Interventions

  • OtherQuestionnaire based intervention

    Three validated questionnaires amended from hepatitis B to D (Chronic liver disease questionnaire, self-stigma scale and HBV virus knowledge scale) will be used.

06

What researchers measure

Primary outcomes

  1. The overall patient understanding of Hepatitis D Virus diagnosis

    Use of modified CLDQ - HBV survey. Scale of 1-7 with lower scores indicating worse outcomes

    Time frame: 6 months

  2. Describe overall patient knowledge around HDV

    Modified HBV knowledge scale survey. Yes or No as options

    Time frame: 6 months

Secondary outcomes

  1. Describe stigma attached towards HDV

    Use of modified Toronto HBV stigma questionnaire. Scale options are: never, rarely, sometimes, often, always

    Time frame: 6 months

  2. Understand satisfaction with communication regarding HDV care at KCH

    Use of local viral hepatitis service questionnaire

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06017375
Responsible party
Sponsor
First posted
Aug 30, 2023
Start date
Sep 1, 2023 (estimated)
Primary completion
Feb 28, 2024 (estimated)
Completion
Aug 30, 2024 (estimated)
Last update
Aug 30, 2023

Study contacts

Sital Shah
Contact
sitalshah@nhs.net
02032999000 ext. 35714

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion